Market Overview

Allergan and Valeant Rally on News of Potential Three Way Deal With Pershing Square

Share:
Related AGN
20 Stocks Moving In Tuesday's Pre-Market Session
Guy Adami And Pete Najarian Share Their Thoughts On Nvidia And Allergan
Braun Stacey Associates Inc Buys Incyte, KB Home, Pinnacle Foods, Sells Vulcan Materials Co, ... (GuruFocus)

Shares of Allergen (NYSE: AGN) and Valeant Pharmaceuticals (NYSE: VRX) are moving higher, gaining 18 percent and 10.7 percent respectively after rumors the former, with the help of Bill Ackman, will acquire the latter for $45 billion, with one third being cash.

The official hostile bid is expected by Tuesday.

Ackman's Pershing Square has reported a 9.7 percent beneficial ownership in Allergan, which includes call options.

Pershing plans to buy $400 million of Valeant's Allergen stake at a 15 percent discount, and may have the right to end the pact if Valeant does not make hostile bid before May 2.

The deal is expected to create $25-$30 per share worth of synergies.

Posted-In: Bill Ackman Pershing SquareNews Hedge Funds M&A General

 

Related Articles (AGN + VRX)

View Comments and Join the Discussion!